TOKYO - Saturday, November 3rd 2012 [ME NewsWire]
Results were presented at the American Society of Nephrology 2012 annual "Kidney Week" meeting and published online in the New England Journal of Medicine (NEJM). The results are intended to form the basis of regulatory filings in multiple countries seeking a new drug approval in ADPKD
Investigational Phase III trial met its primary efficacy endpoint, demonstrating reductions of change in total kidney volume for subjects receiving tolvaptan compared to placebo
ADPKD is the most common inherited cause of kidney failure, accounting for about 5 percent of end-stage renal disease in the U.S. The diagnosed prevalence is estimated to be between 1:1000 and 1:4000 globally
(BUSINESS WIRE)-- Otsuka Pharmaceutical Co., Ltd. today announced that the clinical trial results for tolvaptan, an investigational drug for the treatment of ADPKD, were presented for the first time
...
Read more »